A Multicenter, Single-Arm, Open-Label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma

Trial Profile

A Multicenter, Single-Arm, Open-Label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Pomalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational
  • Acronyms STRATUS
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 17 Jun 2018 Results of a real life analysis assessing long term disease control (n=56) in relapsed/refractory multiple myeloma patients treated with pomalidomide and dexamethasone, previously enrolled in an interventional (STRATUS, MM-010) or currently enrolled in an observational study (MM-015), presented at the 23rd Congress of the European Haematology Association.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Feb 2017 This trial was completed in Poland, according to the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top